G-PUR
Commercial- Indications
- Heavy metal toxicity, Gastrointestinal toxicity, Cholesterol management
Company intelligence / Profile preview
Glock Health
Deutsch Wagram, Lower Austria, Austriaprnewswire.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Glock Health has developed and commercialized G-PUR, a patented dietary supplement based on purified clinoptilolite. The product is marketed for its ability to bind cholesterol, heavy metals, and microbiological toxins in the gastrointestinal tract. The company received an FDA "No Objection Letter" for G-PUR's marketing in the United States.
- Therapeutic areas
- OtherGastroenterology
- Modalities
- Small molecule
- Industry
- Food & Nutrition
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Glock Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glock Health.